todeposit218378659-1-
Guru 3D / Shutterstock.com
4 November 2014Big PharmaPeter ten Haaft

Patent protection for microorganisms

Disclosure of the invention is a requirement for a patent application. A person skilled in the art should be able to perform the invention without undue burden based on the description of the invention in the application. In general, the requirements of disclosure are met by a written description that enables the person skilled in the art to perform a claimed method or to obtain a claimed product. Where a microorganism is involved, a written description may be sufficient to perform a claimed method or to obtain a claimed (biological) product.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.